RB1 and retinoblastoma: As technology facilitates detection of RB1 pathogenic variants and mosaicism [52], it is important that clinical labs report the frequency of RB1 pathogenic variants found among bilaterally affected retinoblastoma patients (the RB1 sensitivity of the test) to support accurate, informed genetic counseling for patients with retinoblastoma and their families.